Abstract
Krystal Biotech Inc. will report third-quarter 2026 results on November 2, 2026 Pre-MKt, with this preview summarizing consensus expectations for revenue, profitability, and adjusted EPS, reviewing last quarter’s performance, and detailing the principal drivers and risks shaping this quarter’s print alongside prevailing analyst views.Market Forecast
Consensus models Krystal Biotech Inc.’s third-quarter revenue at 126.08 million US dollars, implying 35.30% year-over-year growth, alongside an adjusted EPS estimate of 1.77 and EBIT of 58.91 million US dollars, reflecting forecast year-over-year increases of 63.15% and 112.09%, respectively. While explicit margin forecasts are not disclosed, the market’s estimates embed continued operating leverage off a high-efficiency base observed last quarter.The main business remains product revenue, led by the flagship therapy, which delivered 119.22 million US dollars last quarter and grew 24.14% year over year; consensus points to ongoing momentum into the current quarter as commercial execution continues. The most promising segment for near-term growth is also product sales, with total company revenue expected to reach 126.08 million US dollars this quarter, a 35.30% year-over-year increase that implies both continued patient uptake and expanding geographic contribution.
Last Quarter Review
Krystal Biotech Inc. posted last quarter revenue of 119.22 million US dollars, a gross profit margin of 94.60%, GAAP net profit attributable to shareholders of 54.77 million US dollars, a net profit margin of 45.94%, and adjusted EPS of 1.79, which increased 38.76% year over year. A key financial highlight was the combination of a high gross margin base and positive operating leverage that supported robust profitability, even as reported revenue was modestly below consensus.The main business highlight was product revenue of 119.22 million US dollars, which advanced 24.14% year over year, underscoring sustained commercial performance and providing the platform for further scale benefits as the franchise expands.
Current Quarter Outlook
Main business performance drivers
This quarter’s outcome is expected to be driven primarily by the cadence of new patient starts, therapy refills, and continued maturation of payer coverage, which together underpin the consensus revenue estimate of 126.08 million US dollars and a 35.30% year-over-year increase. Sequentially, the revenue trajectory implied by estimates points to a step-up from 119.22 million to 126.08 million US dollars, or approximately 5.75% quarter-over-quarter growth, which would confirm consistent throughput in the commercial channel. With last quarter’s gross profit margin at 94.60% and net profit margin at 45.94%, investors will scrutinize whether the company can hold a similar cost structure as scale increases, given that small changes in gross-to-net dynamics can influence profitability.Adjusted EPS is modeled at 1.77 for the quarter, reflecting 63.15% year-over-year growth, and consensus EBIT of 58.91 million US dollars implies ongoing operating efficiency, though sequential EPS is roughly in line with the prior quarter. This pattern suggests that while revenue is trending higher, opex linked to broader commercial expansion, life-cycle management, and pipeline advancement may partially offset incremental revenue flow-through. Management commentary on unit volume growth, refill rates, and the balance between domestic and international contribution will likely be decisive in explaining both the top-line print and EPS performance.
Most promising business and near-term optionality
The largest growth engine remains the core product franchise, which accounted for essentially all of last quarter’s 119.22 million US dollars of revenue and delivered 24.14% year-over-year growth, and consensus embeds a 35.30% year-over-year gain for total company revenue this quarter. International uptake and broader geographic availability are expected to add to the growth profile over time, and this quarter’s commentary about ex-US traction should help calibrate how rapidly the contribution is building. Momentum in commercial operations, when paired with disciplined cost control, can sustain high gross margins and support solid operating income, as reflected in the consensus EBIT forecast of 58.91 million US dollars, which implies 112.09% year-over-year growth.Beyond the commercial base, early-stage programs add meaningful optionality to the equity story without being modeled as revenue contributors in the current quarter. Recent pilot data for the new dermatology program KB113 in Gorlin syndrome showed substantial lesion regression with favorable tolerability, and the company has begun discussions with the US regulator on advancing clinical development; while non-revenue in the near term, this progress can influence medium-term valuation. The portfolio also includes additional readouts referenced by the Street across ophthalmic and pulmonary applications that, while outside this quarter’s revenue scope, could shape expectations for longer-term operating leverage if successful.
Key factors likely to move the stock around the print
The durability of 90%+ gross margins remains central to the equity narrative, and small variations in gross-to-net adjustments, discounting, or channel mix could have an outsized impact on reported profitability, given last quarter’s 94.60% gross margin starting point. Investors will focus on the balance of US versus international revenue contribution and whether the ex-US markets are beginning to accelerate at a pace sufficient to support the consensus 35.30% year-over-year revenue growth. Any quantitative disclosures on patient additions, refill adherence, or coverage penetration will help reconcile reported revenue with unit-driven metrics and gauge sustainability into subsequent quarters.Operating expenditure trends are the second major swing factor. If selling, general, and administrative expenses rise faster than anticipated due to field force expansion or launch activities in newer geographies, incremental revenue may not fully translate into EPS, which could explain the roughly stable sequential EPS versus last quarter despite higher revenue. Conversely, evidence of operating discipline, such as stable commercial costs per active patient or efficiencies in supply and distribution, could enhance EBIT leverage relative to the 58.91 million US dollars consensus. Finally, pipeline updates—particularly any clarity on timing of next-stage studies for KB113 or additional clinical milestones flagged by analysts—can influence sentiment even if they do not contribute to near-term financials.
Analyst Opinions
The prevailing view among covering institutions is notably positive, with a bullish-to-bearish ratio of 100% to 0% over the past six months. Multiple well-followed firms have recently reiterated or initiated favorable views: Goldman Sachs resumed coverage with a Buy rating and a 441.00 US dollars price target, citing an attractive outlook anchored in the commercial franchise and pipeline potential; RBC Capital initiated with a Buy and a 400.00 US dollars target, highlighting scope for further gains driven by the core product, international launches, and upcoming readouts across the development portfolio. TD Cowen maintained a Buy with a 403.00 US dollars target, while H.C. Wainwright and Chardan also reiterated Buy stances with targets of 310.00 and 323.00 US dollars, respectively, underscoring the breadth of constructive sentiment.The bullish case centers on three pillars that map closely to this quarter’s setup. First, the commercial base continues to expand, and consensus expects 126.08 million US dollars in revenue for the quarter, a 35.30% year-over-year increase, which would validate ongoing patient uptake and geographic scale. Second, profitability metrics have been solid, reflected in last quarter’s 94.60% gross margin and 45.94% net margin, and the Street anticipates continued operating leverage with EBIT forecast at 58.91 million US dollars, up 112.09% year over year. Third, optionality from the pipeline—supported recently by KB113’s pilot data demonstrating broad lesion regression in Gorlin syndrome—provides a supplemental pathway to sustain growth beyond the current commercial asset.
RBC’s recent work further articulates a durable opportunity, emphasizing that international expansion is likely to drive the next phase of growth and noting additional readouts in areas such as ocular dystrophic epidermolysis bullosa and cystic fibrosis that could incrementally broaden the addressable treatment universe. While those programs are not expected to contribute revenue in the current quarter, they can impact valuation frameworks and risk-reward assessments, particularly if timelines and study designs are clarified on the call. Goldman Sachs’ constructive stance aligns with the expectation that the company can defend high margins while scaling revenue, a combination that, if demonstrated again this quarter, supports the consensus outlook for adjusted EPS of 1.77, up 63.15% year over year.
In interpreting these opinions, the majority view expects the quarter to validate the commercial trajectory and margin quality. A print that delivers near-consensus revenue with stable high gross margins and clear commentary on ex-US momentum would likely reinforce the scenario embedded in Buy-rated frameworks. Conversely, if revenue growth falls short of expectations without offsetting margin strength or if updates suggest slower-than-expected ex-US conversion, the case for near-term multiple expansion could be challenged, even as the medium-term pipeline still offers catalysts. Given the concentration of Buy ratings and ambitious price targets, investor attention will be directed toward quantitative markers of scale—revenues near 126.08 million US dollars, adjusted EPS around 1.77, and EBIT approaching 58.91 million US dollars—alongside qualitative details on patient flows and commercialization efficiency that either corroborate or question the consensus path.
Overall, analysts leaning bullish are looking for confirmation that the commercial engine can compound at a healthy pace while preserving a favorable cost structure and that early clinical signals can translate into late-stage progress. With the earnings release scheduled for November 2, 2026 Pre-MKt, the debate will focus on the interplay between top-line acceleration, margin resilience, and visibility on the next set of clinical milestones—factors that together define whether this quarter’s results simply meet expectations or reset the trajectory higher for the coming year.